Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 07454. A webcast of the call will also be available on the Investors & Media section of the Syros website at . An archived replay of the webcast will be available for approximately 30 days following the call.Download as PDF
以 PDF 格式下載
October 24, 2024
2024年10月24日
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals(NASDAQ:SYRS),a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update.
馬薩諸塞州劍橋--(美國商業資訊)--致力於推進血液系統惡性腫瘤一線治療新護理標準的生物製藥公司Syros Pharmicals（納斯達克股票代碼：SYRS）今天宣佈，它將在美國東部時間2024年10月31日星期四上午8點30分舉辦電話會議和網絡直播，以報告其2024年第三季度財務業績並提供業務最新情況。
To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 07454. A webcast of the call will also be available on the Investors & Media section of the Syros website at . An archived replay of the webcast will be available for approximately 30 days following the call.
要觀看電話會議，請撥打 (800) 549-8228（國內）或 (289) 819-1520（國際），並參考會議編號07454。電話會議的網絡直播也將在Syros網站的 「投資者與媒體」 欄目上播出，網址爲。電話會議結束後的大約30天內將提供網絡直播的存檔重播。
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome with RARA gene overexpression. For more information, visit and follow us on Twitter (@SyrosPharma) and LinkedIn.
關於錫羅斯製藥
Syros致力於爲血液系統惡性腫瘤患者的一線治療制定新的護理標準。出於幫助基本上無法採用其他靶向方法的血液疾病患者的動機，Syros正在開發他米巴羅汀，這是一種口服選擇性RARα激動劑，用於治療具有RARA基因過度表達的高風險骨髓增生異常綜合徵的一線患者。欲了解更多信息，請在推特 (@SyrosPharma) 和 LinkedIn 上訪問並關注我們。
View source version on businesswire.com:
在 businesswire.com 上查看源版本：
Syros
Karen Hunady
Director of Corporate Communications & Investor Relations
1-857-327-7321
khunady@syros.com
錫羅斯島
凱倫·胡納迪
企業傳播與投資者關係總監
1-857-327-7321
khunady@syros.com
Investors
Amanda Isacoff
Precision AQ
212-362-1200
amanda.isacoff@precisionaq.com
投資者
阿曼達·艾薩科夫
精度 AQ
212-362-1200
amanda.isacoff@precisionaq.com
Source: Syros Pharmaceuticals
來源：錫羅斯製藥
Released October 24, 2024
2024 年 10 月 24 日發佈
譯文內容由第三人軟體翻譯。
